OQL 033
Alternative Names: OQL-033Latest Information Update: 28 May 2024
At a glance
- Originator OnQuality Pharmaceuticals
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Erythrodysaesthesia
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Erythrodysaesthesia(Chemotherapy-induced) in China
- 31 Mar 2021 Onquality Pharmaceuticals plans clinical trials in Erythrodysaesthesia (Chemotherapy-induced) in 2022
- 21 Apr 2020 OnQuality Pharmaceuticals announces intention to submit IND forErythrodysaesthesia (Chemotherapy-induced) in 2020 (OnQuality Pharmaceutical's pipeline - April 2020)